A Pharmacokinetic and Pharmacogenetic Study in Patients Receiving Sulfamethoxazole-trimethoprim Therapy
- Conditions
- Pneumocystis Jirovecii Pneumonia
- Registration Number
- NCT02045160
- Lead Sponsor
- National Taiwan University Hospital
- Brief Summary
In this study, we aim to investigate the incidence of the adverse reactions, the effectiveness and the gene polymorphism associated with the plasma level of sulfamethoxazole-trimethoprim and their metabolites (including N4-acetyl-sulfamethoxazole, sulfamethoxazole hydroxylamine and sulfamethoxazole-nitroso). And we also aim to investigate the factors associated with the sulfamethoxazole-trimethoprim induced acute psychosis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
- males and females aged 20 years or older
- using oral or intravenous form of sulfamethoxazole-trimethoprim
Exclusion Criteria
- patients who are under 20 years of age
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method High performance liquid chromatography for drug plasma concentration Participants will be followed for the duration of the treatment course, an expected average of 21 days The plasma concentration will not be measured until the patient's treatment course completed.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
National Taiwan University Hospital
🇨🇳Taipei, TW, Taiwan